Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes Journal Article


Authors: Tentori, C. A.; Gregorio, C.; Robin, M.; Gagelmann, N.; Gurnari, C.; Ball, S.; Berrocal, J. C. C.; Lanino, L.; D'Amico, S.; Spreafico, M.; Maggioni, G.; Travaglino, E.; Sauta, E.; Meggendorfer, M.; Zhao, L. P.; Campagna, A.; GenoMed4All; Synthema; GESMD; FISIM; EuroBloodNET; Savevski, V.; Santoro, A.; Al Ali, N.; Sallman, D.; Sole, F.; Garcia-Manero, G.; Germing, U.; Kroger, N.; Kordasti, S.; Santini, V.; Sanz, G.; Kern, W.; Platzbecker, U.; Diez-Campelo, M.; Maciejewski, J. P.; Ades, L.; Fenaux, P.; Haferlach, T.; Zeidan, A. M.; Castellani, G.; Komrokji, R.; Ieva, F.; Della Porta, M. G.
Contributor: Bewersdorf, J. P.
Article Title: Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes
Abstract: PURPOSE Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits and risks of HSCT for patients with MDS, with the timing of transplantation being a crucial question. Here, we aimed to develop and validate a decision support system to define the optimal timing of HSCT for patients with MDS on the basis of clinical and genomic information as provided by the Molecular International Prognostic Scoring System (IPSS-M). PATIENTS AND METHODS We studied a retrospective population of 7,118 patients, stratified into training and validation cohorts. A decision strategy was built to estimate the average survival over an 8-year time horizon (restricted mean survival time [RMST]) for each combination of clinical and genomic covariates and to determine the optimal transplantation policy by comparing different strategies. RESULTS Under an IPSS-M based policy, patients with either low and moderate-low risk benefited from a delayed transplantation policy, whereas in those belonging to moderately high-, high- and very high-risk categories, immediate transplantation was associated with a prolonged life expectancy (RMST). Modeling decision analysis on IPSS-M versus conventional Revised IPSS (IPSS-R) changed the transplantation policy in a significant proportion of patients (15% of patient candidate to be immediately transplanted under an IPSS-R-based policy would benefit from a delayed strategy by IPSS-M, whereas 19% of candidates to delayed transplantation by IPSS-R would benefit from immediate HSCT by IPSS-M), resulting in a significant gain-in-life expectancy under an IPSS-M-based policy (P 5.001). CONCLUSION These results provide evidence for the clinical relevance of including genomic features into the transplantation decision making process, allowing personalizing the hazards and effectiveness of HSCT in patients with MDS. © 2024 by American Society of Clinical Oncology.
Keywords: adult; controlled study; treatment outcome; aged; middle aged; retrospective studies; transplantation, homologous; young adult; gene mutation; major clinical study; genetics; hematopoietic stem cell transplantation; retrospective study; high risk patient; time factors; risk assessment; myelodysplastic syndrome; genomics; allogeneic hematopoietic stem cell transplantation; life expectancy; therapy; allotransplantation; myelodysplastic syndromes; decision support techniques; decision support system; decision support systems, clinical; time factor; procedures; low risk patient; international prognostic scoring system; humans; human; male; female; article; mean survival time; clinical decision support system
Journal Title: Journal of Clinical Oncology
Volume: 42
Issue: 24
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2024-08-20
Start Page: 2873
End Page: 2886
Language: English
DOI: 10.1200/jco.23.02175
PUBMED: 38723212
PROVIDER: scopus
PMCID: PMC11328926
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors